The House Energy and Commerce Health Subcommittee held a hearing on draft bills that would provide clarification on the information that can be included by medical device and drug makers in pre-FDA approval product communication and govern the discussion of off-label use. Subcommittee Chairman Rep. Michael Burgess, R-Texas, said the measures would provide "a targeted approach to addressing the problems presented by our outdated regulatory framework for medical product communication."
House subpanel weighs bills on medical product communication
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.